SMN1 and proximal spinal muscular atrophy: Several studies in animal models of SMA have investigated the inhibition of myostatin as a potential therapeutic target, often utilizing follistatin or follistatin analogues.40,43,49-53 Initial studies using recombinant follistatin administration in the SMN Delta7 mouse model demonstrated increased muscle mass, improved motor performance, and extended survival, regardless of SMN levels.